EUCTR2019-004323-20-DE进行中（未招募）1 期
Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For Parts 1, 2 and 3:
- •-Each patient enrolled in the trial must have CLDN6-positive tumor regardless of tumor histology defined as = 50% of tumor cells expressing = 2+ CLDN6 protein using a semi-quantitative immunohistochemistry (IHC) assay for specific detection of CLDN6 protein expression in formalin-fixed, paraffin-embedded neoplastic tissues.
- •-Must have measurable disease per RECIST 1.1 (except for germ cell tumours).
- •-Germ cell cancer patients without initial measurable disease per RECIST 1.1 and evaluable by cancer antigen (CA)-125, Alphafetoprotein (AFP) or hCG (as applicable] are eligible for the trial.
- •For Parts 1 and 2:
- •-Must have a histologically confirmed solid tumor that is metastatic or unresectable and for which there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy.
- •For Part 2 only:
- •Cohort 7: Vaccine-modulated CLDN6 CAR-T/CLDN6 CAR-T(A) without lymphodepletion
- •- Histologically or cytologically confirmed solid tumor fulfilling inclusion criteria 1-4 that is metastatic or unresectable, and for whom there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy.
- •For Part 3 only:
- •Cohort 1: Testicular cancer
- •-Histologically or cytologically tumor of the testis of any histological subtype that has relapsed and/or is refractory to standard therapy. There is no limit on the number of prior treatment regimens
- •Cohort 2: Ovarian cancer
- •-Histologically or cytologically confirmed ovarian cancer of any histology type including primary peritoneal or fallopian tube tumor that is resistant to a platinum-based chemotherapy regimen. There is no available standard therapy likely to confer clinical benefit to the patient, or they are not a candidate for such available therapy. There is no limit on the number of prior treatment regimens.
- •- Patients without initial measurable disease per RECIST 1.1 and evaluable by CA-125 are eligible for the trial and the tumor response will be assessed by Gynecologic Cancer Intergroup (GCIG) criteria for evaluation of best overall response in patients without initial measurable disease and evaluable by CA-125.
- •Cohort 3: Gastric cancer
- •-Histologically or cytologically confirmed inoperable or metastatic gastric cancer that has failed or demonstrated intolerance to standard therapy - which includes platinum or fluoropyrimidine or taxane based chemotherapy. Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer patient must have failed or demonstrated intolerance to HER2-targeting treatment. There is no limit on the number of prior treatment regimens.
- •Cohort 4: Endometrial cancer
- •-Histologically or cytologically confirmed Endometrial cancer of any histology type that is resistant to a platinum-based chemotherapy regimen, or for whom there is no available standard therapy likely to confer clinical benefit, or patient is not a candidate for such available therapy. There is no limit on the number of prior treatment regimens.
- •Cohort 5: NSCLC
- •-Histological or cytological diagnosis of metastatic non-squamous NSCLC and must have progressed on the standard therapy, including platinum-based chemotherapy and/or checkpoint inhibitor therapy. Patient with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by gene ROS-1 (ROS-1) or human gene encoding proto-oncogene B-Raf (BRAF) mut
排除标准
- •-Has received prior CAR-T therapy, except CLDN6 CAR-T/CLDN6 CART(A) therapy.
- •-Has received vaccination with live virus vaccines within 6 weeks prior to the start of LD.
- •-Receives concurrent systemic (oral or intravenous [i.v.]) steroid therapy > 10 mg prednisolone daily, or its equivalent, for an underlying condition.
- •-Current evidence of new or growing brain or spinal metastases during screening. Patients with known brain or spinal metastases may be eligible if they:
- •-Had radiotherapy or another appropriate therapy for the brain or spinal metastases,
- •-Have no neurological symptoms,
- •-Have stable brain or spinal disease on the computer tomography or magnetic resonance imaging scan within 4 weeks before signing of the informed consent,
- •-Must not be undergoing acute corticosteroid therapy or steroid taper. Chronic steroid therapy is acceptable provided that the dose is stable for the last 14 d prior to screening (= 10 mg prednisolone daily or equivalent),
- •-Do not require steroid therapy within 7 d before the first dose of CLDN6 CAR-T/CLDN6 CAR-T(A),
- •-Spinal bone metastases are allowed, unless imminent fracture or cord compression is anticipated.
- •-Has a history of another primary cancer within the 2 years prior to enrollment except for the following: non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, prostate cancer with currently undetectable prostate specific antigen, or other non-metastatic carcinoma that has been in complete remission without treatment for more than 2 years.
研究者
相似试验
招募中
2 期
A clinical study of the safety and effectiveness of an investigational cell therapy given with and without an investigational RNA-based vaccine in patients with organ tumors2024-514962-38-00BioNTech Cell & Gene Therapies GmbH, BioNTech Cell & Gene Therapies GmbH145
进行中（未招募）
1 期
A study to learn about the safety and efficacy of the study drug product CLDN6 CAR-T with/without the second study drug product CLDN6 RNA-LPX in patients with a specific type of advanced cancer that has reoccurred and does not respond to standard of care treatment.CLDN6-positive relapsed or refractory advanced solid tumorsMedDRA version: 21.0Level: LLTClassification code 10043302Term: Testicular cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10046766Term: Uterine cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10007460Term: Carcinoma of unknown primarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004323-20-NLBioNTech Cell & Gene Therapies GmbH165
招募中
2 期
Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumorstumors10027655cancerNL-OMON54362BioNTech Cell & Gene Therapies GmbH30
进行中（未招募）
1 期
A study to investigate the safety and efficacy of BNT411 in cancer patients with solid tumor types. The study will also assess the safety and efficacy of BNT411 when taken on its own and in combination with standard chemotherapy treatments in patients with late stage small cell lung cancer who have not taken chemotherapy before.Chemotherapy-naïve extensive-stage small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003593-17-ESBioNTech Small Molecules GmbH63
进行中（未招募）
1 期
A study to investigate the safety and efficacy of BNT411 in cancer patients with solid tumor types. The study will also assess the safety and efficacy of BNT411 when taken on its own and in combination with standard chemotherapy treatments in patients with late stage small cell lung cancer who have not taken chemotherapy before.Chemotherapy-naïve extensive-stage small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003593-17-DEBioNTech SE90